REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedRandomized Controlled TrialHuman Subjects

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.

Rubino Domenica M, Greenway Frank L, Khalid Usman, O'Neil Patrick M, Rosenstock Julio, Sørrig Rasmus, Wadden Thomas A, Wizert Alicja, Garvey W Timothy
JAMA2022DOI: 10.1001/jama.2021.23619
semaglutideliraglutide

Quality Score

7/10

Citations

0

Subjects

Human

PeptideVault Analysis

Study Design

As a randomized controlled trial, this study represents the highest tier of clinical evidence. The randomized design controls for confounding variables, making causal inferences more robust than observational studies.

Our Assessment

Quality Assessment: 7/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

The results for semaglutide, liraglutide are encouraging. Critically, these findings come from human data — not animal models or in-vitro work — which makes them directly relevant to clinical applications. The study design adds significant weight to these conclusions.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. Specifically: the follow-up period was relatively short — long-term efficacy and safety remain open questions. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: This is high-quality human evidence for semaglutide, liraglutide. If you're tracking the research landscape for these compounds, this paper deserves a close read.

Key Findings

The study found that once-weekly subcutaneous semaglutide resulted in significantly greater weight loss compared to daily liraglutide among adults with overweight or obesity without diabetes, after a 68-week period.

Limitations

The study had a relatively short follow-up period and did not include participants with diabetes. The open-label design may have influenced participant behavior and reporting of outcomes.

PeptideVault Analysis

Highlighting the comparative effectiveness and patient outcomes between once-weekly semaglutide and daily liraglutide for weight management in non-diabetic obese patients.

semaglutideliraglutide

Weekly Semaglutide Outperforms Daily Liraglutide in Weight Loss for Non-Diabetic Obese Adults

Published: May 17, 2026 | Source: JAMA (2022) | Category: semaglutide, liraglutide

Overview

A recent study published in the Journal of the American Medical Association (JAMA) has shown that once-weekly subcutaneous semaglutide leads to significantly greater weight loss compared to daily liraglutide among adults with overweight or obesity but without diabetes. This finding is crucial for individuals seeking effective peptide therapies for weight management.

Study Background

Previous research had established the efficacy of both glucagon-like peptide-1 (GLP-1) analogues, semaglutide and liraglutide, in managing body weight. However, direct comparisons between these two treatments were lacking. The STEP 8 trial aimed to address this gap by comparing the effectiveness and safety profiles of once-weekly subcutaneous semaglutide at 2.4 mg versus daily liraglutide at 3.0 mg for weight management in non-diabetic obese adults.

What the Research Found

The study, conducted over a period of 68 weeks, involved 338 participants who were randomized to receive either once-weekly semaglutide (126 participants), daily liraglutide (127 participants), or placebo. The primary outcome was percentage change in body weight from baseline. By the end of the study period, those receiving semaglutide experienced an average weight loss of 15.8%, compared to 6.4% for those on liraglutide, representing a significant difference of -9.4 percentage points (p < 0.001). Additionally, more participants in the semaglutide group achieved clinically meaningful weight loss milestones: 72% reached at least 10% weight loss, compared to 35% for liraglutide.

What This Means for Peptide Users

For individuals looking to manage their body weight through peptide therapy and who do not have diabetes, the results suggest that semaglutide may be a more effective option than daily liraglutide. The once-weekly dosing of semaglutide could also offer greater convenience compared to the daily regimen required for liraglutide.

Limitations and Caveats

While the study provides compelling evidence, it is important to note several limitations. First, the trial had a relatively short follow-up period of 68 weeks, which may not fully capture long-term outcomes or side effects. Second, the study excluded participants with diabetes, limiting its applicability to this population. Lastly, the open-label design might have influenced participant behavior and reporting of adverse events.

How This Compares to Previous Research

Previous studies had shown that both semaglutide and liraglutide were effective in promoting weight loss; however, direct comparisons between these two treatments were limited. The STEP 8 trial provides a definitive comparison, highlighting the superior efficacy of semaglutide for non-diabetic obese adults.

Our Analysis

PeptideVault's analysis indicates that this study offers valuable insights into the comparative effectiveness of once-weekly semaglutide versus daily liraglutide for weight management in non-diabetic individuals. The significant difference in weight loss outcomes supports the potential benefits of semaglutide as a preferred treatment option. However, further research is needed to confirm these findings over longer periods and across diverse populations.

Key Takeaways

  • Greater Efficacy: Once-weekly semaglutide resulted in significantly more weight loss compared to daily liraglutide.
  • Convenience Factor: The once-weekly dosing of semaglutide offers a practical advantage for patients.
  • Further Research Needed: Long-term studies and investigations into the effects on diabetic populations are warranted.

Original Source

Citation: Rubino Domenica M, Greenway Frank L, Khalid Usman et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.. JAMA. DOI: 10.1001/jama.2021.23619

Access: https://pubmed.ncbi.nlm.nih.gov/35015037/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was written by the PeptideVault research team to make complex findings accessible to the peptide community. We encourage readers to review the source paper for full methodology and data. For more on semaglutide, explore our research guides.

Citation

Rubino Domenica M, Greenway Frank L, Khalid Usman et al.. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.. JAMA. https://doi.org/10.1001/jama.2021.23619

View full text on PubMed

Related Papers

Medications for Obesity: A Review.

Gudzune Kimberly A et al. · JAMA · 2024

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.

Rubino Domenica et al. · JAMA · 2021

Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.

Silver Heidi J et al. · Diabetes, obesity & metabolism · 2023

Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation.

Khavinson Vladimir et al. · Cells · 2022

A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.

Min Jee Sun et al. · Drug design, development and therapy · 2025

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.